Metropolis Healthcare (METROPOLIS.NS) Stock Price
Metropolis Healthcare Price
Over the last 12 years Metropolis Healthcare grew revenue by 12.8% annually, reaching 16.46 B INR. Earnings per share have grown at 10.6% per year over the last 12 years. For Metropolis Healthcare, the net margin of 11.5% is down versus 17.4% a few years ago. At today's price the dividend yield works out to roughly 0.18%. The payout ratio is around 28% of earnings. The consensus 12-month price target for Metropolis Healthcare is 1,955.85 INR, about 261.2% above where the stock trades today. Of 22 analysts, 16 rate the stock a buy — an overall Buy consensus.
Metropolis Healthcare stock price
Metropolis Healthcare business model & stock analysis
Frequently asked questions about Metropolis Healthcare
Metropolis Healthcare Ltd is a leading provider of diagnostic services in India. Their business model revolves around offering a comprehensive range of medical diagnostic tests and services to patients, healthcare providers, and corporate clients. Metropolis operates through a hub-and-spoke model, with a network of laboratories and patient service centers strategically located across multiple cities. They focus on delivering accurate and timely test results using advanced technology and expert medical professionals. With a strong emphasis on quality and customer satisfaction, Metropolis Healthcare Ltd aims to improve healthcare outcomes by enabling early detection and effective treatment of diseases.
Metropolis Healthcare Ltd is primarily active in the healthcare industry.
The main competitors of Metropolis Healthcare Ltd in the market include Dr. Lal PathLabs Ltd, Thyrocare Technologies Ltd, and SRL Diagnostics.
Metropolis Healthcare Ltd is a renowned company in the healthcare sector with an impressive history and background. Founded in 1980, Metropolis Healthcare has grown to become one of the leading diagnostic companies in India, catering to the diverse needs of patients and healthcare providers. With a focus on delivering accurate, reliable, and timely diagnostics services, Metropolis has expanded its footprint across 7 countries, including India, South Africa, Kenya, and Sri Lanka. The company's commitment to quality, advanced technology, and expert medical professionals has earned it a strong reputation in the industry. Metropolis Healthcare Ltd continues to revolutionize the diagnostics landscape, ensuring better healthcare outcomes for individuals and communities.
Metropolis Healthcare Ltd has achieved several significant milestones. It has expanded its presence to over 125 cities and towns in India, establishing itself as a leading diagnostic company in the country. The company has received accreditation from the National Accreditation Board for Testing and Calibration Laboratories (NABL) for its laboratories across India. Metropolis Healthcare Ltd is also the first laboratory network to be recognized by the National Reference Laboratory in the United Arab Emirates. Furthermore, the company has been awarded the Best Diagnostic Service Provider of the Year by Frost & Sullivan in 2020. These achievements highlight Metropolis Healthcare Ltd's commitment to quality services and its position as a pioneering player in the healthcare industry.
Metropolis Healthcare Ltd is primarily present in India.
Metropolis Healthcare Ltd represents values of excellence, integrity, and innovation in the healthcare industry. With a strong corporate philosophy centered around patient-centricity and quality diagnostics, the company aims to provide accurate and reliable diagnostic solutions to improve patient outcomes. Metropolis Healthcare Ltd is committed to delivering world-class pathology and laboratory services with a focus on advanced technology, skilled professionals, and continuous research and development. As a leading player in the diagnostic industry, the company's goal is to redefine standards and set new benchmarks in healthcare. Through its unwavering commitment to excellence, Metropolis Healthcare Ltd strives to make a positive impact on people's lives.
Analysts currently set an average price target of 1,985.54 INR for the Metropolis Healthcare stock (median: 1,955.85 INR), implying +266.7 % versus the latest price. The consensus is based on 22 analyst ratings.
24 analysts currently rate the Metropolis Healthcare stock: 19 recommend buying, 3 holding and 2 selling.
Converted at the current exchange rate, the Metropolis Healthcare share trades at 5.00 EUR (541.45 INR).
The Metropolis Healthcare share (METROPOLIS.NS) is listed on 2 stock exchanges, including: NSE (Indien) (METROPOLIS.NS).
Metropolis Healthcare Ltd is a leading provider of diagnostic services in India and worldwide. The company was founded in Mumbai in 1980 and has since achieved an impressive track record of growth, focusing on customer needs and introducing innovative technologies and practices. Metropolis Healthcare Ltd comprises four main divisions, each tailored to customer needs and different markets. These divisions include general pathology, oncology, genetics, and microbiology. Each division offers a wide range of tests tailored to specific customer needs. Metropolis Healthcare's general pathology segment includes a wide range of tests for various diseases such as diabetes, liver diseases, kidney disorders, and hormonal disorders. The company utilizes advanced technologies such as polymerase chain reaction (PCR) and immunohistochemistry for precise and rapid diagnoses. Metropolis Healthcare's oncology segment provides tests for various types of cancer. The company has established an extensive network of tumor centers and specialists for cancer diagnosis and treatment. The tests include blood tests, biopsies, and imaging procedures such as computer or magnetic resonance imaging. Metropolis Healthcare's genetics segment offers genetic tests for various diseases such as cancer, heart diseases, or rare genetic disorders. The company is a leader in the application of next-generation sequencing (NGS) for precise genetic diagnoses. Metropolis Healthcare's microbiology segment specializes in infectious diseases. The company has laboratories equipped with state-of-the-art technologies for conducting tests for diseases such as tuberculosis, malaria, dengue fever, and HIV. Metropolis Healthcare also provides a wide range of products needed for disease diagnostics. These products include instruments, test kits, and consumables. The company has partnerships with globally leading companies such as Roche Diagnostics, Siemens Healthcare, and Thermo Fisher Scientific to supply their customers with the latest products and technologies. Metropolis Healthcare's business model is based on a combination of high-quality services, innovative technology, and customer orientation. The company has a strong presence in India and is also expanding into international markets such as Africa, Southeast Asia, and Europe. Metropolis Healthcare has also recently built an increasing presence in telemedicine and digital diagnostics to meet the needs of customers in remote or underserved areas. Overall, Metropolis Healthcare Ltd offers a wide range of diagnostic services and products. The company has established itself as a leading provider of diagnostic services in India and worldwide through its business model and services.
The revenue of Metropolis Healthcare is 16.46 B INR. This figure is based on current financial data and reflects the company's business performance.
The profit of Metropolis Healthcare is 1.90 B INR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Metropolis Healthcare is currently 59.15. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Metropolis Healthcare stock.
The price-to-sales ratio (P/S) of Metropolis Healthcare is currently 6.83. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Metropolis Healthcare stock.
The Eulerpool Quality Score for Metropolis Healthcare is 5/10.
The ISIN of Metropolis Healthcare is INE112L01020. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Metropolis Healthcare is METROPOLIS.NS. The ticker symbol is used to trade Metropolis Healthcare shares on the stock exchange.
Metropolis Healthcare stock
Metropolis Healthcare Peer Group
Metropolis Healthcare Ticker
Metropolis Healthcare FIGI
All fundamentals and in-depth analysis of Metropolis Healthcare
Our stock analysis for Metropolis Healthcare stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Metropolis Healthcare. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.